Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants

AIMS: Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) events by 24% in 12 705 participants at intermediate CV risk after 5.6 years. There was no benefit of blood pressure (BP) lowering treatment in the overall group, but a reduction in events in the third...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosch, Jackie, Lonn, Eva M, Jung, Hyejung, Zhu, Jun, Liu, Lisheng, Lopez-Jaramillo, Patricio, Pais, Prem, Xavier, Denis, Diaz, Rafael, Dagenais, Gilles, Dans, Antonio, Avezum, Alvaro, Piegas, Leopoldo S, Parkhomenko, Alexander, Keltai, Kati, Keltai, Matyas, Sliwa, Karen, Held, Claus, Peters, Ronald J G, Lewis, Basil S, Jansky, Petr, Yusoff, Khalid, Khunti, Kamlesh, Toff, William D, Reid, Christopher M, Varigos, John, Joseph, Philip, Leiter, Lawrence A, Yusuf, Salim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370761/
https://www.ncbi.nlm.nih.gov/pubmed/33963372
http://dx.doi.org/10.1093/eurheartj/ehab225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370761/
https://www.ncbi.nlm.nih.gov/pubmed/33963372
http://dx.doi.org/10.1093/eurheartj/ehab225

Ejemplares similares